Italian plasma specialist Kedrion reveals US investment plan after gaining FDA nod for Qivigy

URLhttps://www.fiercepharma.com/pharma/italian-plasma
SourceFierce Pharma
Date Published09/29/2025
Author Name Kevin Dunleavy

Additional Reshoring Information:

Company/Division name Kedrion Biopharma
Parent companyKedrion Biopharma
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2025
Capital investment ($):260
City reshored to:Melville
State(s) reshored to:NY
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredpharma
What domestic positive factors made reshoring more attractive?Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market
Find Reshoring Articles